Stockscreener 앱 받기
1.04
0.95%
-0.01
시장 영업 전:
1.04
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Will Allogene Therapeutics Inc. benefit from macro trendsMulti-Year Investment Performance Summary Report - Newser
Allogene Therapeutics Inc. stock trend forecastMarket Stability and Long-Term Growth Outlook - Newser
Volume spikes in Allogene Therapeutics Inc. stock – what they meanDaily Trade Monitor with Pattern Alerts - Newser
Can trapped investors hope for a rebound in Allogene Therapeutics Inc.Smart Trend Analysis With Buy Point Cues - Newser
Allogene Therapeutics shares rise 2.86% after-hours following Sumitomo Pharma's submission for Parkinson's disease treatment. - AInvest
Is Allogene Therapeutics Inc. meeting your algorithmic filter criteriaPre-Market Stock Movement Summary and Review - Newser
Follicular Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsights | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Bio - Barchart.com
Allogene Therapeutics Schedules Conference Call and Webcast to Discuss Q2 2025 Financial Results on August 13 - Quiver Quantitative
Allogene Therapeutics announces Q2 2025 financial results, conference call on August 13. - AInvest
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update - Stock Titan
How to integrate Allogene Therapeutics Inc. into portfolio analysis toolsFree Breakout Entry Signal Confirmation Tool - Newser
Allogene Therapeutics shares fall 1.36% intraday after Sumitomo Pharma and RACTHERA submit application for Parkinson's disease treatment. - AInvest
What makes Allogene Therapeutics Inc. stock price move sharplyEquity Signal Recap With Long-Term Summary - Newser
JMP Securities Reiterates Market Perform Rating for Allogene Therapeutics Inc. - AInvest
Allogene Therapeutics Maintains Buy Rating Amid Strategic Adjustments and Technological Advancements - AInvest
Patient Dies After Receiving Monoclonal Antibody Lymphodepletion Regimen in LBCL Trial for Allogene’s Cema-Cel - CGTLive®
Allogene Sticks With Standard Lymphodepletion In CAR-T Trial After Patient Death - insights.citeline.com
Allogene stock maintains Market Perform rating at Citizens JMP after trial adjustment - Investing.com Canada
Allogene stock continues ALPHA3 trial with standard FC regimen after safety event - Investing.com Canada
Allogene Scraps Immunosuppressive Antibody After Patient Death in Lymphoma Trial - BioSpace
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Benzinga
Patient death in Allogene trial - The Pharma Letter
What is Allogene Therapeutics Inc. company’s growth strategyBuild wealth steadily with proven investment strategies - Jammu Links News
What are the technical indicators suggesting about Allogene Therapeutics Inc.High-yield growth strategies - Jammu Links News
When is Allogene Therapeutics Inc. stock expected to show significant growthInvest confidently with market-leading analysis - Jammu Links News
How does Allogene Therapeutics Inc. compare to its industry peersMaximize your portfolio’s growth potential - Jammu Links News
Is it the right time to buy Allogene Therapeutics Inc. stockJaw-dropping returns - Jammu Links News
Is Allogene Therapeutics Inc. stock overvalued or undervaluedMaximize returns with disciplined investment techniques - Jammu Links News
What drives Allogene Therapeutics Inc. stock priceStrong return on assets - Jammu Links News
What are Allogene Therapeutics Inc. company’s key revenue driversUnstoppable profit momentum - Jammu Links News
How many analysts rate Allogene Therapeutics Inc. as a “Buy”Access daily stock market expert updates - Jammu Links News
What is the dividend policy of Allogene Therapeutics Inc. stockGet real-time alerts on high-potential stocks - Jammu Links News
What are the latest earnings results for Allogene Therapeutics Inc.Jaw-dropping returns - Jammu Links News
Allogene Therapeutics updates ALPHA3 trial protocol following safety event By Investing.com - Investing.com Australia
How volatile is Allogene Therapeutics Inc. stock compared to the marketBeginner Investor Report With Low Risk - Jammu Links News
Allogene Therapeutics Faces Market Volatility Amid Financial Challenges - StocksToTrade
Allogene Resets Clinical Course After Patient Death In Lymphoma StudyAllogene Therapeutics (NASDAQ:ALLO) - Benzinga
Regeneron cancer bispecific rejected again; Allogene discloses trial death - BioPharma Dive
Allogene Therapeutics updates ALPHA3 trial protocol following safety event - Investing.com
Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event - TipRanks
RENT Form 144: Insider plans to sell 262 shares worth $1.49k | ALLO SEC FilingForm 8-K - Stock Titan
Allogene Therapeutics Announces Selection of Standard FC Lymphodepletion Regimen in ALPHA3 Study Following Consultation with FDA and Safety Board - Quiver Quantitative
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma - The Manila Times
Allogene says lymphodepletion drug caused patient death, changes CAR-T study design - Endpoints News
Allogene Therapeutics shares rise 2.33% premarket after Robbins LLP class action filing. - AInvest
Understanding Allogene Therapeutics Inc.’s price movementCommunity Entry Consensus Trade Ideas Shared - metal.it
Allogene Therapeutics Inc. Trading Near Value Zone — Recovery AheadWatchlist for Low Risk High Return Stocks Updated - metal.it
RSI Crosses Above 30 for Allogene Therapeutics Inc. — Reversal in SightLow Volatility Stable Growth Picks Rank High - metal.it
Published on: 2025-07-29 12:47:04 - metal.it
CAR-T Cell Therapy Market is projected to grow to US$ 20.4 billion - openPR.com
Allogene Therapeutics Inc. Forms Bullish Flag — Upside AheadLow Drawdown Real Time Trading Tips Shared - metal.it
What is the risk reward ratio of investing in Allogene Therapeutics Inc. stockBest Dividend Forecasts To Watch Now - Jammu Links News
Does Allogene Therapeutics Inc. stock perform well during market downturnsPre Market Ideas For Beginners - Jammu Links News
How does Allogene Therapeutics Inc. generate profit in a changing economyAchieve breakthrough financial results today - Jammu Links News
0.24%
3.39%
자본화:
|
볼륨(24시간):